Ftse Mib
36.471,75
0,12%
DAX
21.732,05
0,01%
S&P 500
6.040,53
-0,50%
NASDAQ
19.627,44
-0,28%
Bitcoin
99.077,13
-1,58%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Kronos Bio Inc (KRON) Kronos Bio Inc (KRON) Notizie

KRON

Kronos Bio (KRON)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRON
DataOraFonteTitoloSimboloCompagnia
27/11/202415:25AllPennyStocks.comCalifornia Biotech Stock Bid Up Prior To Opening Bell On Major AnnouncementNASDAQ:KRONKronos Bio Inc
27/11/202413:30GlobeNewswire Inc.Kronos Bio Announces CEO Transition and Reduction in ForceNASDAQ:KRONKronos Bio Inc
15/11/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KRONKronos Bio Inc
14/11/202422:02GlobeNewswire Inc.Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024NASDAQ:KRONKronos Bio Inc
13/11/202422:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KRONKronos Bio Inc
13/11/202422:05GlobeNewswire Inc.Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic AlternativesNASDAQ:KRONKronos Bio Inc
07/11/202422:47Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:KRONKronos Bio Inc
05/11/202415:00GlobeNewswire Inc.Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaNASDAQ:KRONKronos Bio Inc
23/10/202414:55GlobeNewswire Inc.Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
16/10/202400:57Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
09/10/202414:55GlobeNewswire Inc.Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsNASDAQ:KRONKronos Bio Inc
07/10/202414:55GlobeNewswire Inc.Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s DiseaseNASDAQ:KRONKronos Bio Inc
25/09/202414:55GlobeNewswire Inc.Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory TherapyNASDAQ:KRONKronos Bio Inc
23/09/202414:55GlobeNewswire Inc.Kronos Bio Highlights Data at AACR Ovarian Cancer Research Symposium that Supports Clinical Evaluation of Istisociclib in Advanced Ovarian CancerNASDAQ:KRONKronos Bio Inc
03/09/202414:55GlobeNewswire Inc.Kronos Bio Announces Participation in Medical and Investor Conferences in SeptemberNASDAQ:KRONKronos Bio Inc
08/08/202422:15GlobeNewswire Inc.Kronos Bio Reports Second Quarter 2024 Financial Results and Pipeline UpdateNASDAQ:KRONKronos Bio Inc
08/08/202422:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KRONKronos Bio Inc
23/07/202422:15GlobeNewswire Inc.Kronos Bio Announces First Patient Dosed with KB-0742 in an Expansion Cohort Focused on Platinum-Resistant High-Grade Serous Ovarian CancerNASDAQ:KRONKronos Bio Inc
04/06/202422:58Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KRONKronos Bio Inc
23/05/202423:15GlobeNewswire Inc.Kronos Bio to Present Clinical Update on Phase 1/2 Trial of KB-0742 at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingNASDAQ:KRONKronos Bio Inc
22/05/202422:30GlobeNewswire Inc.Kronos Bio to Participate in Three Upcoming Healthcare Conferences and EventsNASDAQ:KRONKronos Bio Inc
21/05/202422:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:KRONKronos Bio Inc
21/05/202414:15GlobeNewswire Inc.Kronos Bio Appoints Deborah Knobelman, Ph.D. as Chief Operating Officer and Chief Financial Officer NASDAQ:KRONKronos Bio Inc
09/05/202422:05GlobeNewswire Inc.Kronos Bio Reports First-Quarter 2024 Financial ResultsNASDAQ:KRONKronos Bio Inc
21/03/202412:05GlobeNewswire Inc.Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2023 Financial ResultsNASDAQ:KRONKronos Bio Inc
07/03/202422:05GlobeNewswire Inc.Kronos Bio Announces Restructuring to Focus Resources on Clinical Development with Extended Cash RunwayNASDAQ:KRONKronos Bio Inc
05/03/202422:44GlobeNewswire Inc.Kronos Bio To Present Three Posters at AACR 2024 Annual MeetingNASDAQ:KRONKronos Bio Inc
27/02/202422:05GlobeNewswire Inc.Kronos Bio Announces Participation in 44th Annual Cowen Health Care ConferenceNASDAQ:KRONKronos Bio Inc
18/12/202322:06GlobeNewswire Inc.Kronos Bio Announces Pipeline Update and p300 KAT Inhibitor Development CandidateNASDAQ:KRONKronos Bio Inc
04/12/202314:00GlobeNewswire Inc.Kronos Bio Announces Participation in H.C. Wainwright 4th Annual Precision Oncology Virtual ConferenceNASDAQ:KRONKronos Bio Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:KRON

La tua Cronologia

LSE
BVIC
Britvic
LSE
GIL5
Am Ukgov 0-5y
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci